After years of off-label workarounds and compounded pharmacy formulations, people with eosinophilic esophagitis finally have an FDA-approved pill they can swallow. Eohilia, a budesonide oral suspension manufactured by Takeda Pharmaceuticals, received FDA approval on February 12, 2024, and became commercially available just eight days later on February 20, 2024. It is the first and only FDA-approved oral therapy for EoE, a chronic immune-mediated disease that causes inflammation and scarring in the esophagus, making swallowing painful and sometimes dangerous. For the estimated one in 700 Americans living with EoE — and for the caregivers of older adults whose swallowing difficulties may overlap with or be worsened by this condition — the approval marks a genuine turning point.
Consider a 68-year-old woman who has spent years assuming her difficulty swallowing was simply part of aging or related to her cognitive decline, only to learn through an endoscopy that eosinophils have been quietly ravaging her esophageal tissue. Before Eohilia, her doctor might have prescribed a proton pump inhibitor off-label or asked her to swallow a slurry mixed from a crushed asthma inhaler — an approach that was inconsistent in dosing and unpleasant to use. Now there is a standardized, clinically tested oral option. This article covers how Eohilia works and what its clinical trials actually showed, the real-world cost and insurance picture, how it compares to the injectable biologic Dupixent, what side effects to watch for — particularly in older or cognitively impaired patients — and what new oral therapies are moving through the pipeline.
Table of Contents
- What Is the New Oral Drug for Eosinophilic Esophagitis, and How Does It Work?
- The Cost of Eohilia and What Insurance Actually Covers
- How Eohilia Compares to Dupixent, the Other FDA-Approved EoE Treatment
- Side Effects Caregivers and Patients Should Watch For
- Why EoE Is Often Missed in Older Adults and People With Dementia
- Europe’s Head Start With Jorveza and What It Tells Us
- What Is Coming Next in the EoE Treatment Pipeline
- Conclusion
- Frequently Asked Questions
What Is the New Oral Drug for Eosinophilic Esophagitis, and How Does It Work?
Eohilia is a budesonide oral suspension, meaning it delivers a topical corticosteroid directly to the esophageal lining as the patient swallows. The approved dose is 2.0 mg taken twice daily for a 12-week treatment course, and it is indicated for patients aged 11 years and older. Unlike systemic steroids that circulate through the entire body and carry well-known risks for bone density and immune suppression, budesonide in this formulation is designed to act locally on the inflamed esophageal tissue before being largely metabolized by the liver. That distinction matters enormously for older adults, who are already more vulnerable to steroid side effects. The FDA’s approval rested on two randomized, double-blind, placebo-controlled 12-week studies enrolling patients aged 11 to 56. In Study 1, 53.1 percent of patients taking Eohilia achieved histologic remission — meaning their esophageal biopsies showed eosinophil counts had dropped below the disease threshold — compared to just 1 percent on placebo.
Study 2 showed a 38 percent remission rate versus 2.4 percent on placebo. Those are not subtle differences. Beyond the biopsy numbers, patients also reported meaningful improvements in dysphagia symptoms: a reduction of 10.2 points on a standardized symptom scale versus 6.5 for placebo in the first study, and 14.5 versus 5.9 in the second. It is worth noting, however, that histologic remission and feeling better are not always the same thing. some patients achieved tissue-level improvement without dramatic symptom relief, and others felt better before their biopsies normalized. For caregivers monitoring an older adult with dementia who may not be able to articulate changes in swallowing comfort, this distinction is important — objective follow-up with a gastroenterologist remains necessary even when things seem to be going well.
The Cost of Eohilia and What Insurance Actually Covers
The wholesale acquisition cost for Eohilia is $1,875 for a 30-day supply, and retail cash prices range from approximately $1,927 to $2,524 for 60 unit-dose packets covering a month of treatment. At those prices, a full 12-week course could run well over $5,000 out of pocket without insurance — a number that puts it out of reach for many families, particularly those already managing the financial burden of dementia care or other chronic conditions. Takeda offers a manufacturer copay card for commercially insured patients that can reduce out-of-pocket costs to as little as $0, covering up to $2,500 per year. That sounds generous, but there are important caveats.
The copay card typically does not apply to patients on Medicare, Medicaid, or other government insurance programs, which means the very population most likely to be managing EoE alongside age-related conditions may not qualify for the discount. Additionally, Eohilia is distributed exclusively through specialty pharmacies, not standard retail pharmacies, which can add logistical hurdles — delayed shipments, prior authorization requirements, and limited pharmacist availability for questions. If you or someone you care for is on a fixed income or government insurance, it is worth contacting Takeda’s patient assistance program directly and asking a social worker or case manager to help navigate options. Some specialty pharmacies also have their own financial assistance coordinators. Do not assume the sticker price is the final price, but also do not assume the copay card will solve everything.
How Eohilia Compares to Dupixent, the Other FDA-Approved EoE Treatment
Before Eohilia’s approval, the only FDA-approved treatment for EoE was Dupixent (dupilumab), a biologic injection first approved for EoE in May 2022 for patients aged 12 and older, with an expanded approval in January 2024 covering children as young as one year old weighing at least 15 kilograms. Dupixent works through an entirely different mechanism — it blocks interleukin-4 and interleukin-13 signaling, which are key drivers of the type 2 inflammatory response behind EoE. In clinical trials, 100 percent of patients receiving weekly dupilumab injections achieved 15 or fewer eosinophils per high-power field after 52 weeks, with greater than 95 percent reduction in peak eosinophil counts. Those efficacy numbers are remarkable, but context matters. Dupixent requires regular subcutaneous injections, either self-administered or given by a caregiver, which is a significant practical barrier for someone with cognitive impairment or limited dexterity. Eohilia, by contrast, is an oral suspension that the patient simply swallows.
For a dementia caregiver assisting with medication management, the difference between helping someone drink a measured liquid dose and administering an injection is substantial. Dupixent also carries its own side effect profile and cost considerations, and its long-term use model — ongoing injections rather than a defined 12-week course — changes the commitment calculus. The choice between the two is not straightforward. If a patient has failed or cannot tolerate topical steroids, Dupixent may be the better path. If ease of administration and a shorter initial treatment course are priorities, Eohilia has clear advantages. A gastroenterologist familiar with both options, ideally one who understands the patient’s full medical picture including any cognitive or functional limitations, should guide this decision.
Side Effects Caregivers and Patients Should Watch For
The most commonly reported side effects in Eohilia’s clinical trials were respiratory tract infection at 13 percent, gastrointestinal mucosal candidiasis at 8 percent, headache at 5 percent, gastroenteritis at 3 percent, throat irritation at 3 percent, adrenal suppression at 2 percent, and erosive esophagitis at 2 percent. For most patients, these are manageable. But for older adults, particularly those with compromised immune function or existing swallowing difficulties, a few of these deserve closer attention. Oral and esophageal candidiasis — essentially a yeast infection in the mouth or throat — is a known risk with any topical corticosteroid that contacts mucosal tissue. In cognitively impaired patients who may not report mouth pain or white patches on their tongue, caregivers need to physically check the mouth periodically during treatment.
Left untreated, candidiasis can worsen swallowing problems and lead to reduced food intake, which spirals quickly in someone already at nutritional risk. Adrenal suppression at 2 percent is a lower-frequency concern, but it becomes more relevant if the patient is also taking inhaled or nasal corticosteroids for asthma or allergies — the cumulative steroid load adds up. The tradeoff is real but generally favorable. Uncontrolled EoE carries its own serious risks: esophageal strictures, food impaction requiring emergency removal, chronic malnutrition, and significant reduction in quality of life. For most patients, the benefit of achieving histologic remission outweighs the manageable side effects of a 12-week course, but ongoing monitoring is non-negotiable.
Why EoE Is Often Missed in Older Adults and People With Dementia
Eosinophilic esophagitis has historically been framed as a disease of younger men — and the epidemiologic data supports a higher prevalence in males, at roughly 204 cases per 100,000 compared to 122 per 100,000 in females. But the broader prevalence picture has shifted dramatically. EoE now affects approximately one in 700 people in the United States, representing a five-fold increase since 2009, and the associated annual healthcare costs have reached an estimated $1.3 billion in 2024 dollars. This is not a rare curiosity. It is an increasingly common condition that may be hiding behind other diagnoses. In older adults with dementia, EoE symptoms — difficulty swallowing, food avoidance, unexplained weight loss, chest discomfort during meals — are easily attributed to the dementia itself or to normal aging.
A person with moderate Alzheimer’s who begins refusing solid foods might be assumed to have entered a new stage of cognitive decline, when the actual cause could be an inflamed esophagus making every bite painful. Without a clinician who thinks to order an endoscopy with biopsies, the diagnosis is missed entirely. This diagnostic blind spot is dangerous. If someone in your care has developed new or worsening swallowing difficulties, particularly if they also have a history of allergies, asthma, or eczema — all conditions associated with EoE — push for a gastroenterology referral. The availability of effective oral treatment makes the case for accurate diagnosis even more compelling. There is now something concrete to offer beyond dietary elimination and watchful waiting.
Europe’s Head Start With Jorveza and What It Tells Us
Patients in Europe have had access to an approved oral EoE treatment since January 2018, when the European Medicines Agency approved Jorveza, a budesonide orodispersible tablet. In clinical trials, 58 percent of patients achieved reduced eosinophil levels and no or minimal symptoms at six weeks compared to zero percent on placebo. After 48 weeks of maintenance therapy, approximately 74 to 75 percent of patients maintained satisfactory symptom control versus just 4 percent on placebo — numbers that speak to the value of ongoing treatment rather than a single short course.
Jorveza’s long European track record is informative for American patients and caregivers wondering what to expect from oral budesonide therapy over time. The maintenance data in particular suggests that many patients may need continued treatment beyond an initial 12-week course to sustain remission. If your gastroenterologist recommends extended therapy or a repeated course of Eohilia, that recommendation is consistent with what European clinicians have observed over nearly a decade of real-world use.
What Is Coming Next in the EoE Treatment Pipeline
The pipeline of oral EoE therapies in development suggests that Eohilia will not be the only option for long. Etrasimod, a once-daily oral S1P receptor modulator, showed a 52.4 percent reduction in peak eosinophil counts at the 2 mg dose over 24 weeks in a Phase 2b study, compared to a 61 percent increase in eosinophil counts on placebo. Roughly 33 percent of patients on etrasimod achieved histologic remission. Notably, etrasimod is not a steroid — it works through an entirely different immune pathway, which could be important for patients who cannot tolerate corticosteroids or who need a long-term non-steroidal maintenance strategy.
Phathom Pharmaceuticals began Phase 2 dosing of VOQUEZNA (vonoprazan) for EoE in November 2025. Vonoprazan is a potassium-competitive acid blocker rather than a traditional proton pump inhibitor, representing another non-steroidal oral approach. APT-1011, a fluticasone propionate orally disintegrating tablet, is also in development. Each of these candidates addresses a slightly different piece of the puzzle — steroid alternatives, novel mechanisms, and more convenient formulations. For patients and caregivers frustrated by the current cost or access barriers with Eohilia, competition in this space should eventually improve both pricing and availability.
Conclusion
The approval and commercial availability of Eohilia represents the most significant practical advance in EoE treatment in years. For the first time, patients and their caregivers have an FDA-approved oral medication with solid clinical evidence — remission rates of 38 to 53 percent versus near-zero on placebo — and a defined 12-week treatment course. Alongside Dupixent’s injectable option and a growing pipeline of non-steroidal alternatives, the EoE treatment landscape has moved from near-total reliance on off-label improvisation to genuine therapeutic choice.
For caregivers of older adults with dementia or cognitive impairment, the key takeaway is twofold. First, swallowing difficulties in your loved one may deserve a closer look than they are getting — EoE is increasingly common and frequently underdiagnosed in this population. Second, if the diagnosis is confirmed, effective oral treatment now exists. Talk to a gastroenterologist, ask about Eohilia, understand the cost and insurance picture before filling the prescription, and monitor for side effects — particularly oral candidiasis and any signs of adrenal issues — throughout the course of treatment.
Frequently Asked Questions
Is Eohilia a cure for eosinophilic esophagitis?
No. Eohilia is approved for a 12-week treatment course and can achieve histologic remission in a significant percentage of patients, but EoE is a chronic condition. European data with a similar budesonide therapy (Jorveza) suggests many patients need ongoing or repeated treatment to maintain remission.
Can someone with dementia safely take Eohilia?
There is no specific contraindication related to dementia. However, the patient must be able to swallow the oral suspension safely. If your loved one has severe dysphagia or is at risk for aspiration, discuss the administration method with their gastroenterologist before starting.
Is Eohilia available at regular pharmacies?
No. Eohilia is distributed exclusively through specialty pharmacies, which may require additional steps such as prior authorization from insurance and coordination with the prescribing physician’s office.
Does Medicare cover Eohilia?
Coverage varies. Medicare Part D plans may cover Eohilia, but the manufacturer’s copay card — which can reduce costs to $0 for commercially insured patients — typically does not apply to Medicare beneficiaries. Contact your Part D plan and Takeda’s patient assistance program for specifics.
What is the difference between Eohilia and Dupixent for EoE?
Eohilia is an oral suspension (swallowed liquid) containing a topical corticosteroid, approved for a 12-week course. Dupixent is an injectable biologic that works on a different immune pathway and is used on an ongoing basis. Dupixent showed higher remission rates in long-term studies but requires regular injections and carries different side effects.
Are there non-steroidal oral options coming for EoE?
Yes. Etrasimod (an S1P modulator) and VOQUEZNA (vonoprazan, a potassium-competitive acid blocker) are both in clinical development and represent non-steroidal oral approaches. Neither is FDA-approved yet.
